

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,214	03/01/2005	Tsuyoshi Maekawa	10525.0004	7396
22852 7590 08/17/2007 FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER		EXAMINER		
LLP			JAISLE, CECILIA M	
901 NEW YORK AVENUE, NW WASHINGTON, DC 20001-4413		ART UNIT	PAPER NUMBER	
	,		1624	
			MAY DATE	DEL MEDITA CODE
			MAIL DATE	DELIVERY MODE
			08/17/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
		MAEKAWA ET AL.				
Office Action Summary	10/517,214					
• • • • • • • • • • • • • • • • • • •	Examiner	Art Unit				
The MAILING DATE of this communication app	Cecilia M. Jaisle	1624				
Period for Reply		oon oop on a one o a can ood				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period was period to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ti vill apply and will expire SIX (6) MONTHS from cause the application to become AB ANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 23 No.	Responsive to communication(s) filed on 23 November 2004.					
· <u> </u>	, -					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
closed in accordance with the practice under E	x paπe Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-33</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) ☐ Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	. 1 4!					
8)⊠ Claim(s) <u>1-33</u> are subject to restriction and/or €	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	e Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the prior	rity documents have been receiv	ed in this National Stage				
application from the International Bureau						
* See the attached detailed Office action for a list	of the certified copies not receiv	ed.				
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summar Paper No(s)/Mail D					
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal 6) Other:					

DETAILED OFFICE ACTION

Lack of Unity

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions that are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1-31, drawn to substituted Pyrazole compounds of Formula I, classified in class 548, subclasses 373.1 and 375.1, *inter alia*, pharmaceutical compositions thereof and therapeutic methods using compounds of Group I, classified in class 514, subclasses 403 and 404, *inter alia*.
- II. Claims 1-31, drawn to substituted Isoxazole compounds of Formula I, classified in class 548, subclasses 240, 243, 245, inter alia, pharmaceutical compositions thereof and therapeutic methods using Group II compounds, classified in class 514, subclasses 378, *inter alia*.
- III. Claims 1-31, drawn to all other substituted 1,2-Azole compounds of Formula I, classified variously in class 544, and pharmaceutical compositions thereof and therapeutic methods using compounds of Group III, classified variously in class 514.
- IV. Claim 32, drawn to a method of producing a compound of the formula II-1, classified variously in class 544.
- V. Claim 33, drawn to a formula IX compound, classified variously in class 544.

Art Unit: 1624

Each group as set forth above lacks unity with each other group, i.e., there is no single general inventive concept. The unique special technical features in each group are the identities of the nitrogen containing 1,2-azole ring of Formula I and the other nitrogen containing 1,2-azole rings of other Formulae of the disclosure. The technical relationship among the inventions does not involve at least one common or corresponding special technical feature. The expression "special technical feature" is defined as meaning those technical features that define the contribution which each claimed invention, considered as a whole, makes over the prior art. In this case, a reference that could be used to reject substituted Pyrazole compounds of Formula I of Group I could not be used to reject substituted Isoxazole compounds of Formula I of Group II.

The Group I invention has special technical features not common to Group II and would be expected to be useful other than as disclosed, e.g., as PPAR ligand receptor binders (WO 06/064888). Also, the Group II invention has special technical features not common to Group I and would be expected to be useful other than as disclosed, e.g., as crop protection agents (CA Pat. 2100546).

A telephone call was made to Mr. Charles E. Van Horn on Aug. 10, 2007 to request an oral election to the above restriction requirement, but did not result in an election being made.

To preserve a right to petition, the reply to this Office Action must distinctly and specifically point out supposed errors in the restriction requirement, or the election shall be treated as an election without traverse.

Art Unit: 1624

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cecilia M. Jaisle, J.D. whose telephone number is 571-272-9931. The examiner can normally be reached on Monday through Friday; 8:30 am through 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/517,214 Page 5

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Cecilia M. Jaisle, J.D. 8/14/2007

JAMES O. WILSON
SUPERVISORY PATENT EXAMIN

/ TECHNOLOGY CENTER 1600